Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
Nivolumab +1 More for Follicular Lymphoma
Recruiting1 awardPhase 1
Saint Louis, Missouri
This trial is testing a combination of a personalized tumor vaccine with nivolumab to treat follicular lymphoma. The goal is to create a well tolerated therapy without cumulative and long-term toxicity. If this combination is successful, it may be used to treat patients with other monoclonal antibodies against CD20.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.